Abstract:Background Previous genome-wide association studies (GWAS) have identified several risk genes for stroke; however, it remains unclear how they confer risk for the disease. We conducted an integrative analysis to identify candidate genes for stroke and stroke subtypes by integrating blood-derived multi-omics data with genetic data. Method We systematically integrated the latest stroke GWAS database (73,652 patients and 1,234,808 controls) with human plasma proteomes (N=7,213) and performed proteome-wide association studies (PWAS), Mendelian randomization (MR), Bayesian colocalization analysis, and transcriptome-wide association study (TWAS) to prioritize genes that associate the risk of stroke and its subtypes with their expression and protein abundance in plasma. Cell-type specificity and functional enrichment analysis using single-cell RNA sequencing (scRNA-seq) and Gene Ontology (GO) databases were then performed to select target genes. A two-step MR analysis was followed to explore the potential mechanisms. Results We found that the protein abundance of seven genes ( MMP12, F11, SH3BGRL3, ENGASE, SCARA5, SWAP70, and SPATA20 ) in the plasma was associated with stroke and its subtypes, with six genes ( MMP12, F11, SH3BGRL3, SCARA5, SWAP70, and SPATA20 ) causally related with stroke and its subtypes (P < 0.05/proteins identified for PWAS; P < 0.05/8 for MR; posterior probability of hypothesis 4 ≥ 75 % for Bayesian colocalization). The effect of F11, SH3BGRL, SPATA20, and SWAP70 on each subtype was mediated by Factor XI inhibitors (FXI), atrial fibrillation, T2D, and SBP respectively (p<0.05). We also found that SCARA5 and SWAP70 were related to stroke and ischemic stroke at the transcriptome level. Conclusions Our present proteomic findings have identified new causal genes in the pathogenesis of stroke, which may offer potential future therapeutic targets for stroke prevention. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was partially supported by grants from the National Natural Science Foundation of China (No. 81400979 and 81870931), the SanHang Program of the Naval Medical University, and the ?Climbing? program of Changhai Hospital. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: NONE I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data in the manuscript is truly usable

Proteomics Reveals Plasma Biomarkers for Ischemic Stroke Related to the Coagulation Cascade

Identification of Blood Biomarkers in Ischemic Stroke by Integrated Analysis of Metabolomics and Proteomics

Abstract 13: Aptamer-Based Plasma Proteomics Nominates Biomarkers Of Neurological Severity, Stroke Diagnosis And Age

Plasma Proteomics Reveals Coagulation, Inflammation, and Metabolic Shifts in H-type Hypertension Patients with and Without Acute Ischemic Stroke.

Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis

Plasma protein alterations during human large vessel stroke: A controlled comparison study

Preliminary study of proteomics of blood stasis syndrome of ischemic stroke

From Analysis of Ischemic Mouse Brain Proteome to Identification of Human Serum Clusterin As a Potential Biomarker for Severity of Acute Ischemic Stroke

Plasma heart-type fatty acid binding protein level in acute ischemic stroke: comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome

Blood-based protein biomarkers during the acute ischemic stroke treatment window: a systematic review

Proteomics Analysis of Brain Tissue in a Rat Model of Ischemic Stroke in the Acute Phase

Potential Biomarkers of Acute Ischemic Stroke Etiology Revealed by Mass Spectrometry-Based Proteomic Characterization of Formalin-Fixed Paraffin-Embedded Blood Clots

Subtyping strokes using blood‐based protein biomarkers: A high‐throughput proteomics and machine learning approach

Identification of Site-Specific Stroke Biomarker Candidates by Laser Capture Microdissection and Labeled Reference Peptide

Isobaric Tags for Relative and Absolute Quantitation-Based Quantitative Serum Proteomics Analysis in Ischemic Stroke Patients With Hemorrhagic Transformation

Discovery of Metabolite Biomarkers for Acute Ischemic Stroke Progression

Serum-Based Proteomics Reveals Lipid Metabolic and Immunoregulatory Dysregulation in Cervical Artery Dissection with Stroke

Biomarkers for acute diagnosis and management of stroke in neurointensive care units

Gene Expression Profiling of Blood for the Prediction of Ischemic Stroke

Proteomic advance of ischemic stroke: preclinical, clinical, and intervention

Identification of Potential Therapeutic targets for Stroke and Its Subtypes by Integrating Proteomes and Genetics from Human Plasma